Ciliotherapy: A Novel Intervention in Polycystic Kidney Disease

Authors

Sarmed H. Kathem, Chapman UniversityFollow
Ashraf M. Mohieldin, University of Toledo
Shakila Abdul-Majeed, University of Toledo
Sajida H. Ismail, University of Baghdad
Qaiss H. Altaei, Kidney Disease & Transplant Center
Ibrahim K. Alshimmari, Alkadhumia Academic Hospital
Mohanned M. Alsaidi, Alkadhumia Academic Hospital
Hussein Khammas, Alkadhumia Academic Hospital
Andromeda M. Nauli, East Tennessee State UniversityFollow
Bina Joe, University of Toledo
Surya M. Nauli, Chapman UniversityFollow

Document Type

Article

Publication Date

2014

Abstract

Background Ciliopathies are a group of diseases associated with abnormal structure or function of primary cilia. Ciliopathies include polycystic kidney disease (PKD), a pathology associated with vascular hypertension. We previously showed that cilia length regulates cilia function, and cilia function is required for nitric oxide (NO) biosynthesis in endothelial cells. Because patients with PKD show abnormal sensory cilia function, the aim of our current study was to search for a targeted therapy focused on primary cilia, which we refer to as ‘cilio-therapy’.

Methods and Results In the present studies, our in vitro analyses refined fenoldopam as an equipotent and more specific dopa- minergic agonist to regulate cilia length and function.

Comments

This article was originally published in Journal of Geriatric Cardiology, volume 11, in 2014. DOI: 10.3969/j.issn.1671-5411.2014.01.001

Recommended Citation

Kathem SH, Mohieldin AM, Abdul-Majeed S, Ismail SH, Altaei QH, Alshimmari IK, Alsaidi MM, Khammas H, Nauli AM, Joe B, Nauli SM. Ciliotherapy: a novel intervention in polycystic kidney disease. J Geriatr Cardiol. 2014; 11: 63-73.
DOI: 10.3969/j.issn.1671-5411.2014.01.001

Copyright

Institute of Geriatric Cardiology/Science Press

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.